| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 42 | 2024 | 1260 | 4.700 |
Why?
|
| CD4 Antigens | 8 | 2022 | 49 | 1.820 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 3 | 2022 | 52 | 1.560 |
Why?
|
| HIV Infections | 31 | 2024 | 5097 | 1.540 |
Why?
|
| Drug Resistance, Viral | 10 | 2024 | 278 | 1.390 |
Why?
|
| Receptors, CXCR4 | 7 | 2020 | 28 | 1.030 |
Why?
|
| Molecular Sequence Data | 20 | 2015 | 263 | 0.960 |
Why?
|
| Receptors, CCR5 | 7 | 2020 | 54 | 0.840 |
Why?
|
| Genotype | 12 | 2024 | 442 | 0.810 |
Why?
|
| Antibodies, Neutralizing | 4 | 2022 | 303 | 0.770 |
Why?
|
| Genome, Viral | 4 | 2009 | 64 | 0.760 |
Why?
|
| HIV Reverse Transcriptase | 4 | 2024 | 41 | 0.720 |
Why?
|
| Anti-Retroviral Agents | 6 | 2018 | 551 | 0.720 |
Why?
|
| HIV Antibodies | 4 | 2022 | 247 | 0.670 |
Why?
|
| Humans | 43 | 2024 | 14537 | 0.660 |
Why?
|
| HIV Envelope Protein gp120 | 8 | 2022 | 104 | 0.650 |
Why?
|
| Mutation | 5 | 2024 | 306 | 0.640 |
Why?
|
| Viral Tropism | 2 | 2020 | 9 | 0.630 |
Why?
|
| HIV Integrase | 3 | 2014 | 6 | 0.560 |
Why?
|
| HIV Long-Term Survivors | 2 | 2009 | 8 | 0.560 |
Why?
|
| Human Immunodeficiency Virus Proteins | 3 | 2015 | 10 | 0.530 |
Why?
|
| Amino Acid Sequence | 12 | 2014 | 139 | 0.520 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2024 | 118 | 0.500 |
Why?
|
| Drug Carriers | 1 | 2015 | 93 | 0.490 |
Why?
|
| Consensus Sequence | 1 | 2014 | 4 | 0.470 |
Why?
|
| Founder Effect | 1 | 2014 | 16 | 0.470 |
Why?
|
| Genetic Variation | 4 | 2010 | 175 | 0.460 |
Why?
|
| Sequence Analysis, DNA | 9 | 2016 | 181 | 0.450 |
Why?
|
| Leuconostoc | 4 | 1998 | 4 | 0.440 |
Why?
|
| Bacteriocins | 4 | 1998 | 5 | 0.440 |
Why?
|
| AIDS Vaccines | 1 | 2015 | 152 | 0.440 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 472 | 0.420 |
Why?
|
| South Africa | 19 | 2024 | 7596 | 0.410 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 3 | 2016 | 29 | 0.410 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 1324 | 0.400 |
Why?
|
| Disulfides | 4 | 2018 | 6 | 0.400 |
Why?
|
| Phylogeny | 9 | 2010 | 231 | 0.390 |
Why?
|
| Antibodies, Bispecific | 2 | 2022 | 20 | 0.360 |
Why?
|
| Sequence Deletion | 1 | 2010 | 16 | 0.360 |
Why?
|
| RNA, Viral | 6 | 2013 | 303 | 0.360 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2009 | 472 | 0.340 |
Why?
|
| Binding Sites | 6 | 2018 | 43 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 198 | 0.310 |
Why?
|
| HIV Envelope Protein gp160 | 2 | 2005 | 22 | 0.300 |
Why?
|
| Protein Binding | 6 | 2018 | 62 | 0.300 |
Why?
|
| Adult | 13 | 2020 | 5913 | 0.290 |
Why?
|
| Genes, vpr | 1 | 2007 | 2 | 0.280 |
Why?
|
| Genes, vpu | 1 | 2007 | 2 | 0.280 |
Why?
|
| Genes, vif | 1 | 2007 | 2 | 0.280 |
Why?
|
| Recombination, Genetic | 3 | 2003 | 27 | 0.270 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 187 | 0.270 |
Why?
|
| Female | 16 | 2020 | 9103 | 0.260 |
Why?
|
| Phenotype | 4 | 2024 | 158 | 0.250 |
Why?
|
| Protein Conformation | 3 | 2018 | 24 | 0.250 |
Why?
|
| Protein Structure, Secondary | 4 | 2018 | 12 | 0.250 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2024 | 198 | 0.250 |
Why?
|
| Thioredoxins | 2 | 2016 | 3 | 0.250 |
Why?
|
| Gene Products, env | 3 | 2014 | 11 | 0.250 |
Why?
|
| Oxidation-Reduction | 4 | 2018 | 24 | 0.250 |
Why?
|
| Protein Structure, Tertiary | 4 | 2018 | 22 | 0.240 |
Why?
|
| Recombinant Proteins | 5 | 2018 | 73 | 0.240 |
Why?
|
| Thymidine | 1 | 2024 | 6 | 0.240 |
Why?
|
| Protein Multimerization | 2 | 2022 | 8 | 0.240 |
Why?
|
| Triazoles | 1 | 2024 | 20 | 0.240 |
Why?
|
| Male | 12 | 2020 | 6754 | 0.230 |
Why?
|
| Drug Resistance, Multiple, Viral | 3 | 2014 | 16 | 0.230 |
Why?
|
| Siblings | 1 | 2003 | 2 | 0.220 |
Why?
|
| Pyridones | 1 | 2024 | 100 | 0.220 |
Why?
|
| Treatment Failure | 4 | 2018 | 175 | 0.210 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2014 | 33 | 0.210 |
Why?
|
| Sequence Alignment | 5 | 2008 | 59 | 0.200 |
Why?
|
| Protein Interaction Domains and Motifs | 3 | 2018 | 13 | 0.200 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2015 | 27 | 0.190 |
Why?
|
| HIV | 2 | 2018 | 380 | 0.180 |
Why?
|
| Receptors, HIV | 2 | 2013 | 12 | 0.170 |
Why?
|
| Mutation, Missense | 3 | 2016 | 65 | 0.170 |
Why?
|
| Viral Proteins | 2 | 2010 | 30 | 0.170 |
Why?
|
| Killer Cells, Natural | 2 | 2010 | 52 | 0.170 |
Why?
|
| Sequence Homology, Amino Acid | 5 | 2014 | 27 | 0.170 |
Why?
|
| Middle Aged | 7 | 2016 | 3601 | 0.160 |
Why?
|
| Cell Membrane | 2 | 2016 | 10 | 0.160 |
Why?
|
| DNA, Viral | 3 | 2009 | 165 | 0.160 |
Why?
|
| Antigen Presentation | 2 | 2015 | 6 | 0.160 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2018 | 1 | 0.150 |
Why?
|
| Protein Subunits | 1 | 2018 | 4 | 0.150 |
Why?
|
| Glutathione | 1 | 2018 | 4 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2018 | 20 | 0.150 |
Why?
|
| Neutralization Tests | 3 | 2022 | 108 | 0.150 |
Why?
|
| Animals | 2 | 2015 | 1081 | 0.150 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2018 | 25 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Genes, env | 2 | 2008 | 9 | 0.150 |
Why?
|
| Membrane Microdomains | 1 | 2016 | 1 | 0.130 |
Why?
|
| Allosteric Site | 1 | 2016 | 2 | 0.130 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 92 | 0.130 |
Why?
|
| Rabbits | 1 | 2015 | 35 | 0.130 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2015 | 1 | 0.130 |
Why?
|
| Base Sequence | 4 | 2014 | 149 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 11 | 0.130 |
Why?
|
| HEK293 Cells | 3 | 2022 | 39 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 10 | 0.120 |
Why?
|
| Child | 4 | 2014 | 2242 | 0.120 |
Why?
|
| Didanosine | 1 | 2014 | 11 | 0.120 |
Why?
|
| Cell Line | 4 | 2010 | 93 | 0.120 |
Why?
|
| Malawi | 1 | 2014 | 87 | 0.120 |
Why?
|
| Zambia | 1 | 2014 | 115 | 0.110 |
Why?
|
| Meat Products | 1 | 1994 | 2 | 0.110 |
Why?
|
| Food Microbiology | 1 | 1994 | 4 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 58 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2010 | 151 | 0.100 |
Why?
|
| Viral Load | 5 | 2018 | 819 | 0.100 |
Why?
|
| Cloning, Molecular | 2 | 2018 | 26 | 0.100 |
Why?
|
| Coordination Complexes | 1 | 2011 | 1 | 0.100 |
Why?
|
| Gold | 1 | 2011 | 38 | 0.090 |
Why?
|
| Codon | 1 | 2010 | 7 | 0.090 |
Why?
|
| Sequence Homology | 1 | 2010 | 11 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2010 | 65 | 0.090 |
Why?
|
| Pyrrolidinones | 1 | 2010 | 6 | 0.090 |
Why?
|
| Quinolones | 1 | 2010 | 7 | 0.090 |
Why?
|
| Raltegravir Potassium | 1 | 2010 | 14 | 0.090 |
Why?
|
| Genes, Viral | 1 | 2009 | 11 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1422 | 0.080 |
Why?
|
| Giant Cells | 1 | 2008 | 3 | 0.080 |
Why?
|
| Glycosylation | 1 | 2008 | 17 | 0.080 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2007 | 28 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 111 | 0.070 |
Why?
|
| Gene Products, vpr | 1 | 2007 | 2 | 0.070 |
Why?
|
| Gene Products, vif | 1 | 2007 | 2 | 0.070 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 2 | 0.070 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 2 | 0.070 |
Why?
|
| Sequence Analysis, Protein | 1 | 2007 | 10 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2004 | 37 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2018 | 84 | 0.070 |
Why?
|
| Evolution, Molecular | 2 | 2007 | 60 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 2 | 2016 | 3 | 0.070 |
Why?
|
| Kinetics | 2 | 2018 | 65 | 0.070 |
Why?
|
| Bacteria | 2 | 1997 | 47 | 0.060 |
Why?
|
| Baculoviridae | 1 | 2005 | 1 | 0.060 |
Why?
|
| Spodoptera | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2008 | 967 | 0.060 |
Why?
|
| Deoxyadenosines | 1 | 2024 | 2 | 0.060 |
Why?
|
| Gene Products, gag | 1 | 2005 | 11 | 0.060 |
Why?
|
| Young Adult | 3 | 2016 | 2498 | 0.060 |
Why?
|
| Prevalence | 3 | 2016 | 1192 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2015 | 656 | 0.060 |
Why?
|
| Adolescent | 3 | 2016 | 2985 | 0.060 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2004 | 5 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2004 | 9 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 142 | 0.060 |
Why?
|
| Gene Products, rev | 1 | 2003 | 2 | 0.060 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2003 | 2 | 0.060 |
Why?
|
| Protein Folding | 2 | 2016 | 4 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 77 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 60 | 0.050 |
Why?
|
| Africa, Central | 1 | 2003 | 7 | 0.050 |
Why?
|
| Africa, Northern | 1 | 2003 | 5 | 0.050 |
Why?
|
| Africa, Western | 1 | 2003 | 8 | 0.050 |
Why?
|
| Africa, Eastern | 1 | 2003 | 17 | 0.050 |
Why?
|
| Africa, Southern | 1 | 2003 | 91 | 0.050 |
Why?
|
| Parents | 1 | 2022 | 32 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 150 | 0.050 |
Why?
|
| Aged | 2 | 2016 | 1740 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2015 | 16 | 0.040 |
Why?
|
| Virus Replication | 2 | 2014 | 88 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 7 | 0.040 |
Why?
|
| Epitopes | 1 | 2019 | 97 | 0.040 |
Why?
|
| Circular Dichroism | 1 | 1998 | 1 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 1998 | 6 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2018 | 4 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 1 | 2018 | 4 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 10 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2018 | 30 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2018 | 8 | 0.040 |
Why?
|
| Gene Expression | 1 | 2018 | 43 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2018 | 55 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 112 | 0.040 |
Why?
|
| Genes, Bacterial | 2 | 1994 | 23 | 0.040 |
Why?
|
| Plasmids | 2 | 1994 | 23 | 0.040 |
Why?
|
| Gene Products, pol | 1 | 2016 | 5 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 38 | 0.030 |
Why?
|
| Dithionitrobenzoic Acid | 1 | 2016 | 1 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2016 | 5 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 15 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 4 | 0.030 |
Why?
|
| World Health Organization | 1 | 2016 | 137 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 71 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 65 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 56 | 0.030 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2015 | 1 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2015 | 20 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 45 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 34 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 260 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 468 | 0.030 |
Why?
|
| Meat | 1 | 1994 | 3 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 45 | 0.030 |
Why?
|
| Lovastatin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 11 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2014 | 79 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 563 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 38 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 91 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 265 | 0.030 |
Why?
|
| Dimerization | 1 | 2014 | 4 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2014 | 19 | 0.030 |
Why?
|
| Dideoxynucleosides | 1 | 2014 | 29 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 25 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
|
| Food Preservation | 1 | 1994 | 2 | 0.030 |
Why?
|
| Tenofovir | 1 | 2015 | 171 | 0.030 |
Why?
|
| Stavudine | 1 | 2014 | 78 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2011 | 56 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 39 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 48 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 77 | 0.020 |
Why?
|
| Automation | 1 | 2009 | 8 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 55 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 14 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 67 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 107 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 385 | 0.020 |
Why?
|
| Ghana | 1 | 2007 | 67 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 154 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 6 | 0.020 |
Why?
|
| Heteroduplex Analysis | 1 | 2005 | 4 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2009 | 1479 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2009 | 529 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 799 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 1862 | 0.010 |
Why?
|
| Proviruses | 1 | 2003 | 6 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2003 | 16 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 2244 | 0.010 |
Why?
|
| Chemistry, Physical | 1 | 1994 | 2 | 0.010 |
Why?
|
| Food Contamination | 1 | 1994 | 3 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1994 | 6 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1994 | 16 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1994 | 3 | 0.010 |
Why?
|